CRISPR CSO departs as Celgene continues to sell stock – FierceBiotech
FierceBiotech |
CRISPR CSO departs as Celgene continues to sell stock
FierceBiotech In the absence of Lundberg, Tony Ho, M.D., will oversee CRISPR’s R&D activities. CRISPR appointed Ho, who previously worked at AstraZeneca and Merck, as its head of R&D in August. Ho inherits a broad preclinical pipeline of ex vivo and in vivo CRISPR … CRISPR Therapeutics Announces Transition of Bill Lundberg, MDGlobeNewswire (press release) Why Crispr Therapeutics AG Stock Bolted Higher in JanuaryMotley Fool Analysts Layout Best- And Worst-Case Scenarios: CRISPR Therapeutics AG (CRSP), Diodes Incorporated (DIOD)Post Analyst The Ledger Gazette –StockNewsTimes –StockNewsGazette all 27 news articles » |
NBCNews.com |
This woman’s family is fighting to make it easier for organ donors to come to the US
NBCNews.com Eight months later, Huynh successfully underwent a stem cell transplant. But on Jan. 26, at the age of 61 and nearly a year after her diagnosis, Huynh lost her battle with cancer. Huynh’s family blames her death in part to a delay in the transplant … |
NBCNews.com |
This woman’s family is fighting to make it easier for organ donors to come to the US
NBCNews.com Eight months later, Huynh successfully underwent a stem cell transplant. But on Jan. 26, at the age of 61 and nearly a year after her diagnosis, Huynh lost her battle with cancer. Huynh’s family blames her death in part to a delay in the transplant … |